Your shopping cart is currently empty

RN277 is an inhibitor of LRRK2 type II kinase (LRRK2type II kinase). It serves as a cellular tool targeting the inactive state of LRRK2. In vitro, RN277 inhibits LRRK1 kinase activity and the kinase activity of LRRK2, with an IC50 of 70 nM. Additionally, it reduces Rab8a phosphorylation in a dose-dependent manner. RN277 is useful for Parkinson's disease research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | RN277 is an inhibitor of LRRK2 type II kinase (LRRK2type II kinase). It serves as a cellular tool targeting the inactive state of LRRK2. In vitro, RN277 inhibits LRRK1 kinase activity and the kinase activity of LRRK2, with an IC50 of 70 nM. Additionally, it reduces Rab8a phosphorylation in a dose-dependent manner. RN277 is useful for Parkinson's disease research. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.